Charoenlarp K, Jaroonvesama N
J Int Med Res. 1978;6(1):67-71. doi: 10.1177/030006057800600112.
Acebutolol (Sectral) was used successfully in a clinical trial involving thirty-two hypertensive patients. Twenty-three patients received acebutolol at a dosage of 400--800 mg daily as sole treatment and nine patients received concurrent treatment with thiazide diuretics. In both groups of patients there was a substantial fall in diastolic and systolic pressure to levels within the normotensive range. The combination of acebutolol with thiazide diuretics was a particularly effective form of anti-hypertensive treatment where a greater anti-hypertensive effect was required. Acebutolol did not significantly slow the heart rate. The only side-effect was slight pitting oedema of both legs in one patient. Acebutolol appears to be a useful anti-hypertensive in the management of hypertension.
醋丁洛尔（塞达洛尔）在一项涉及32名高血压患者的临床试验中取得了成功。23名患者每日服用400 - 800毫克醋丁洛尔作为唯一治疗药物，9名患者同时接受噻嗪类利尿剂治疗。两组患者的舒张压和收缩压均大幅下降至正常血压范围。在需要更强降压效果时，醋丁洛尔与噻嗪类利尿剂联合使用是一种特别有效的抗高血压治疗方式。醋丁洛尔不会显著减慢心率。唯一的副作用是1名患者出现双侧小腿轻度凹陷性水肿。醋丁洛尔似乎是治疗高血压的一种有用的抗高血压药物。
